NIH funds $45m in new Alzheimer's research; Lilly, Roche drugs to be tested
This article was originally published in Scrip
Executive Summary
Even in a time of constrained fiscal resources, the National Institutes of Health (NIH) must capitalize on "exciting scientific opportunities" to advance the understanding of the biology of Alzheimer's disease and find effective therapies as quickly as possible, said the agency's chief, Dr Francis Collins, who unveiled plans on 18 September to fund $45m in new research.